Navigation Links
Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
Date:9/12/2009

SAN DIEGO, Sept. 12 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of torezolid at the low 200 mg dose against methicillin-sensitive and methicillin-resistant bacteria in patients with severe complicated skin and skin structure infections (cSSSI). In vitro studies presented at ICAAC highlight the potency of torezolid against linezolid-resistant MRSA and cfr-mediated resistant bacteria.

"The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid," said Philippe Prokocimer, M.D., chief medical officer at Trius." There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways."

ICAAC data presentations are as follows:

Saturday, September 12

(Poster Session 024, 11:30 am - 1:30 pm)

  • L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)

(Poster Session 004, 11:30 am - 1:30 pm)

  • B-050/52: Comparative Efficacy of TR-701, Vancomycin (Vanco), and Daptomycin (Dapto) in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Endocarditis

Sunday, September 13

(Poster Session 082a, 11:15 am - 1:15 pm)

  • E-808/275: Activity of Torezolid against linezolid-resistant MRSA strains with cfr gene mediated resistance
  • E-807/274: Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain
  • E-809/276: In Vitro Activity of Torezolid (TR-700) versus Linezolid against Chlamydia species

Monday, September 14

(Poster Session 155, 11:15 am - 1:15 pm)

  • C1-1346/84: Unexpectedly low cost of fitness associated with acquisition of the cfr resistance gene
  • C1-1364b/104: Genetic Environment and Instability of cfr in MRSA CM05
  • C1-1364a/103: In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial
  • C1-1349/87: Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin

Tuesday, September 15

(Poster Session 226, 9:00 am - 11:00 am)

  • A1-1939/12: Compararative Pharmacodynamics of a Novel Oxazolidinone, TR-701, Against S. aureus in a Neutropenic Murine Pneumonia Infection Model
  • A1-1935/8: Defining the Impact of Granulocytes (G) on the Kill of Methicillin-Resistant Staphylococcus aureus (MRSA) by the New Oxazolidanone Prodrug TR-701
  • A1-1947/20: Evaluation of Tissue Distribution of TR-700 in Healthy Volunteers, Using Microdialysis
  • A1-1934/7: Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid

Copies of these posters will be available on the Trius Web site following the ICAAC meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
2. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
3. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Trius Doses First Patient in Antibacterial Phase 2 Trial
6. PacificGMP Completes GMP Product Fill for Trius Therapeutics
7. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
8. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
9. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
10. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
11. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
Breaking Medicine Technology:
(Date:5/24/2016)... Santa Rosa, California (PRWEB) , ... May 24, ... ... management (PHM) technology, debuted a new corporate identity and website at its “Transforming ... brand, website, and other marketing enhancements reflect i2i’s ongoing success to set the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... A ... will rely heavily on their access to trusted resources, both in face-to-face interactions and ... Young Men of Color,” researchers concluded that the creative use of mobile digital devices ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... increased by 9.3 million people, or 10% over last year, according to data ... covered under group policies was comparatively stable, with a slight decrease in risk-based ...
Breaking Medicine News(10 mins):